Back to Search Start Over

Prognostic impact of BCL2 and MYC expression and translocation in untreated DLBCL: Results from the phase III GOYA study.

Authors :
Martelli M.
Sehn L.H.
Oestergaard M.Z.
Trneny M.
Bosi A.
Egyed M.
Vitolo U.
Illes A.
Nakamae H.
Opat S.
Topp M.
Zaja F.
Fingerle-Rowson G.
Lei G.
Nielsen T.
Punnoose E.A.
Rahman M.
Ray J.
Zhang L.
Martelli M.
Sehn L.H.
Oestergaard M.Z.
Trneny M.
Bosi A.
Egyed M.
Vitolo U.
Illes A.
Nakamae H.
Opat S.
Topp M.
Zaja F.
Fingerle-Rowson G.
Lei G.
Nielsen T.
Punnoose E.A.
Rahman M.
Ray J.
Zhang L.
Publication Year :
2017

Abstract

Introduction: DLBCL pts with tumours co-expressing BCL2 and MYC (dual-expressor, DE) or with dual gene translocations (double-hit, DH) have poor outcomes but prognostic relationships between cell-of-origin (COO) subtype (ABC vs GCB) and BCL2/MYC are unclear. We report predefined exploratory analyses of the prognostic effects of BCL2 positivity (+), MYC+, DE and DH, in relation to COO, in the Phase III GOYA study (NCT01287741). Method(s): Pts with previously untreated DLBCL were randomised 1:1 to receive obinutuzumab or rituximab plus 6 or 8 cycles of CHOP. Using a Ventana investigational-use IHC assay (BCL2 antibody clone, 124; c-MYC, Y69), pretreatment tumour samples were analysed at a central laboratory. Samples stained within the limit of BCL2 (<=4 months, 30degreeC) and MYC (<=12 months, 30degreeC) antigen stability were included in primary analyses; sensitivity analyses included all samples. Scoring algorithm incorporated % of tumour cells stained and intensity: BCL2 IHC+, moderate/strong in >=50% of tumour cells; MYC IHC+, >=40% of tumour cells. Vysis LSI Dual Color Break Apart FISH Probes identified BCL2 and MYC translocations: FISH+, >=50%. COO classification of RNA extracts used a NanoString Lymphoma Subtyping gene expression assay. Univariate Cox regression analysis of investigator-assessed PFS was performed. Covariates for multivariate analysis were treatment arm (Tx), IPI score, no. of CHOP cycles and COO. (Figure Presented) Results: Baseline characteristics, including IPI score, were similar for biomarker evaluable and ITT populations. Prevalence of BCL2 IHC+, MYC IHC+, DE and DH was 49%, 83%, 42% and 3.6%, respectively. Prevalence by COO: BCL2 IHC+, 75% in ABC and 38% in GCB; MYC IHC+, 95% in ABC and 76% in GCB; DE, 72% in ABC and 29% in GCB; DH, 7% in GCB and 0% in ABC (19/20 DH pts were GCB; 1 unclassified). In univariate analysis, BCL2 IHC+, DE and DH were associated with poorer prognosis (Table). Multivariate analysis confirm the poor prognosis of

Details

Database :
OAIster
Publication Type :
Electronic Resource
Accession number :
edsoai.on1305109484
Document Type :
Electronic Resource